– USA, CA – DNA Script, a leader in Enzymatic DNA Synthesis, today announced the appointments of Don Kania (Ph.D.) to the Board of Directors as Chairman alongside Catherine Moukheibir and Bonnie Anderson joining the Board as Independent Director, bringing together decades of life sciences experience to the Board.
Catherine Moukheibir will also join the Audit Committee as Chair.
“DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform,” said co-founder and CEO, Thomas Ybert. “We now have the first, initial demonstration of the true promise of EDS technology — the ability to produce quick, clean, and high-quality synthetic DNA in a benchtop solution to expedite life science discoveries. This is only the beginning; we have barely started. As we continue to expand the company and explore what is possible with EDS technology, the new board members’ partnership and counsel will be invaluable.”
About Dr. Don Kania
For over thirty years, Dr. Don Kania has been an influential member of the life sciences industry. Notably, he served as the CEO of FEI Company from 2006 until 2016, when the company was sold to Thermo-Fisher for $4.2 billion. Kania currently advises several startups and serves on several boards that span the life sciences and nonprofit sectors.
About Catherine Moukheibir
Moukheibir brings over 30 years of leadership experience in finance, capital markets, and life sciences to DNA Script. Most recently, Moukheibir was the chair and CEO of MedDay Pharmaceuticals. She currently serves on the Board of Directors at Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals Inc, and Orphazyme. Before her current roles, she has held senior management positions at several European biotech companies following an initial career in strategy consulting and investment banking in Boston and London.
“I firmly believe DNA Script’s EDS technology will have a profound impact on genomics and synthetic biology. The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets. This is an incredibly exciting time for the company,” said Board Chairman, Dr. Don Kania. “I have spent my career helping companies grow into life science leaders. I am looking forward to applying my experience and working closely with the Board and the company’s leadership and founders to expand the applications of EDS and grow DNA Script’s DNA-on-demand offerings.”
About Bonnie Anderson
Her career spans over 40 years in regulated diagnostics and life science markets. She co-founded Veracyte in 2008 and served as CEO and Chairman of the Board until June 1, 2021, when she assumed the role of Executive Chairwoman. She led Veracyte’s initial public offering in 2013, spearheaded the commercialization of its market-leading products, and was the architect of the company’s vision to become a global enterprise with a growing menu of advanced genomic diagnostics tests and its own distributed instrument platform.
About DNA Script
Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful, and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy.
For more information: https://www.dnascript.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.